Annals of Pediatric Endocrinology & Metabolism (Sep 2015)

Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma

  • Ju Hyun Ahn,
  • Wan Hyeong Cho,
  • Jun Ah Lee,
  • Dong Ho Kim,
  • Ju-Hee Seo,
  • Jung Sub Lim

DOI
https://doi.org/10.6065/apem.2015.20.3.150
Journal volume & issue
Vol. 20, no. 3
pp. 150 – 154

Abstract

Read online

PurposeOsteoporosis is currently receiving particular attention as a sequela in survivors of childhood osteosarcoma. The aim of this study was to evaluate bone mineral density (BMD) changes during methotrexate-based chemotherapy in children and adolescents with osteosarcoma.MethodsNine patients with osteosarcoma were included in this retrospective study and compared with eight healthy controls. BMD of the lumbar spine and unaffected femur neck of patients was serially measured by dual-energy x-ray absorptiometry (DXA) before and just after chemotherapy and compared with controls.ResultsFour patients (44%) showed decreased lumbar spine BMD and seven patients (78%) showed decreased femur neck BMD, while all controls showed increased lumbar and femur BMD (P=0.024 and P=0.023). The femur neck BMD z-scores decreased from -0.49±1.14 to -1.63±1.50 (P=0.032). At the end of therapy, five patients (56%) showed femur neck BMD z-scores below -2.0.ConclusionThe bone metabolism is disturbed during therapy in children with osteosarcoma, resulting in a reduced BMD with respect to healthy controls. Since a reduced BMD predisposes to osteoporosis, specific attention and therapeutic interventions should be considered.

Keywords